Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969888 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT03969888 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 78 participants.
The verdict
NCT03969888, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
Interventions
- DRUG ABBV-3067
- DRUG Placebo ABBV-3067
- DRUG ABBV-2222
- DRUG Placebo ABBV-2222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03969888
The ClinicalTrials.gov registry entry for NCT03969888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ABBV-3067 is the first listed.
NCT03969888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03969888 about?
NCT03969888 is a clinical study titled "A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222". This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
What is the current status of trial NCT03969888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2019-12-11. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT03969888?
The interventions under investigation include: ABBV-3067 (DRUG), Placebo ABBV-3067 (DRUG), ABBV-2222 (DRUG), Placebo ABBV-2222 (DRUG).
Who is sponsoring clinical trial NCT03969888?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.